As a reversible inhibitor that targets both CPT1A and CPT1B, perhexiline maintains anti-cancer efficacy while demonstrating reduced cardiotoxicity in preclinical chronic lymphocytic leukemia (CLL) and hepatocellular carcinoma (HCC) [105,106]. This evidence concerns the gene CPT1B and hepatocellular carcinoma.